211 related articles for article (PubMed ID: 32358087)
21. Efficacy and safety of selective internal radiotherapy versus sorafenib for intermediate-locally advanced hepatocellular carcinoma: a systematic review and meta-analysis.
Zou J; Zhu W; Meng H; Luo P; Zhang J
Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):271-279. PubMed ID: 30791765
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Liver-Directed Concurrent Chemoradiotherapy and Sequential Sorafenib for Advanced Hepatocellular Carcinoma: A Prospective Phase 2 Trial.
Kim BK; Kim DY; Byun HK; Choi HJ; Beom SH; Lee HW; Kim SU; Park JY; Ahn SH; Seong J; Han KH
Int J Radiat Oncol Biol Phys; 2020 May; 107(1):106-115. PubMed ID: 32084526
[TBL] [Abstract][Full Text] [Related]
23. Radionuclide therapy for hepatocellular carcinoma.
Lambert B; Van Vlierberghe H; Troisi R; Defreyne L
Acta Gastroenterol Belg; 2010; 73(4):484-8. PubMed ID: 21299159
[TBL] [Abstract][Full Text] [Related]
24. Sorafenib combined with radiofrequency ablation as treatment for patients with hepatocellular carcinoma: a systematic review and meta-analysis.
Chen L; Ma X; Liu X; Cui X
J BUON; 2017; 22(6):1525-1532. PubMed ID: 29332348
[TBL] [Abstract][Full Text] [Related]
25. Resin Versus Glass Microspheres for
Van Der Gucht A; Jreige M; Denys A; Blanc-Durand P; Boubaker A; Pomoni A; Mitsakis P; Silva-Monteiro M; Gnesin S; Lalonde MN; Duran R; Prior JO; Schaefer N
J Nucl Med; 2017 Aug; 58(8):1334-1340. PubMed ID: 28082436
[TBL] [Abstract][Full Text] [Related]
26. Alternative treatment strategies to sorafenib in patients with advanced hepatocellular carcinoma: a meta-analysis of randomized Phase III trials.
Wang H; Wang H; Yu Z; Liu H
Onco Targets Ther; 2018; 11():5195-5201. PubMed ID: 30214225
[TBL] [Abstract][Full Text] [Related]
27. Predictive value of platelet-to-lymphocyte and neutrophil-to-lymphocyte ratio in HCC treated with sorafenib and radioembolization.
Öcal O; Kimm MA; Hoang TPT; Pech M; Öcal E; Ben Khaled N; Sangro B; Ricke J; Seidensticker M; Wildgruber M
JHEP Rep; 2024 Apr; 6(4):100995. PubMed ID: 38440069
[TBL] [Abstract][Full Text] [Related]
28. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial.
Park JW; Kim YJ; Kim DY; Bae SH; Paik SW; Lee YJ; Kim HY; Lee HC; Han SY; Cheong JY; Kwon OS; Yeon JE; Kim BH; Hwang J
J Hepatol; 2019 Apr; 70(4):684-691. PubMed ID: 30529387
[TBL] [Abstract][Full Text] [Related]
29. Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) Versus Best Supportive Care in Patients With Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy: Safety and Efficacy Cohort Study.
Xing M; Prajapati HJ; Dhanasekaran R; Lawson DH; Kokabi N; Eaton BR; Kim HS
Am J Clin Oncol; 2017 Feb; 40(1):27-34. PubMed ID: 25089529
[TBL] [Abstract][Full Text] [Related]
30. Outcomes of Radioembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Invasion: Resin versus Glass Microspheres.
Biederman DM; Titano JJ; Tabori NE; Pierobon ES; Alshebeeb K; Schwartz M; Facciuto ME; Gunasekaran G; Florman S; Fischman AM; Patel RS; Nowakowski FS; Kim E
J Vasc Interv Radiol; 2016 Jun; 27(6):812-821.e2. PubMed ID: 27062356
[TBL] [Abstract][Full Text] [Related]
31. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma.
Kolligs FT; Bilbao JI; Jakobs T; Iñarrairaegui M; Nagel JM; Rodriguez M; Haug A; D'Avola D; op den Winkel M; Martinez-Cuesta A; Trumm C; Benito A; Tatsch K; Zech CJ; Hoffmann RT; Sangro B
Liver Int; 2015 Jun; 35(6):1715-21. PubMed ID: 25443863
[TBL] [Abstract][Full Text] [Related]
32. Current role of selective internal radiation with yttrium-90 in liver tumors.
Lau WY; Teoh YL; Win KM; Lee RC; de Villa VH; Kim YH; Liang PC; Santos-Ocampo RS; Lo RH; Lim KB; Tai DW; Ng DC; Irani FG; Gogna A; Chow PK
Future Oncol; 2016 May; 12(9):1193-204. PubMed ID: 27007495
[TBL] [Abstract][Full Text] [Related]
33. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.
Johnson PJ; Qin S; Park JW; Poon RT; Raoul JL; Philip PA; Hsu CH; Hu TH; Heo J; Xu J; Lu L; Chao Y; Boucher E; Han KH; Paik SW; Robles-Aviña J; Kudo M; Yan L; Sobhonslidsuk A; Komov D; Decaens T; Tak WY; Jeng LB; Liu D; Ezzeddine R; Walters I; Cheng AL
J Clin Oncol; 2013 Oct; 31(28):3517-24. PubMed ID: 23980084
[TBL] [Abstract][Full Text] [Related]
34. Safety and Efficacy of Selective Internal Radionuclide Therapy with
Bellendorf A; Mader N; Mueller SP; Ezziddin S; Bockisch A; Grafe H; Best J; Goebel J; Pöppel TD; Sabet A
Pharmaceuticals (Basel); 2024 Jan; 17(1):. PubMed ID: 38256934
[TBL] [Abstract][Full Text] [Related]
35. Underlying liver disease influences volumetric changes in the spared hemiliver after selective internal radiation therapy with 90Y in patients with hepatocellular carcinoma.
Teo JY; Goh BK; Cheah FK; Allen JC; Lo RH; Ng DC; Goh AS; Khor AY; Sim HS; Ng JJ; Chow PK
J Dig Dis; 2014 Aug; 15(8):444-50. PubMed ID: 24828952
[TBL] [Abstract][Full Text] [Related]
36. A retrospective analysis of selective internal radiation therapy (SIRT) with yttrium-90 microspheres in patients with unresectable hepatic malignancies.
Omed A; Lawrance JA; Murphy G; Laasch HU; Wilson G; Illidge T; Tipping J; Zivanovic M; Jeans S
Clin Radiol; 2010 Sep; 65(9):720-8. PubMed ID: 20696299
[TBL] [Abstract][Full Text] [Related]
37. The Post-SIR-Spheres Surgery Study (P4S): Retrospective Analysis of Safety Following Hepatic Resection or Transplantation in Patients Previously Treated with Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres.
Pardo F; Sangro B; Lee RC; Manas D; Jeyarajah R; Donckier V; Maleux G; Pinna AD; Bester L; Morris DL; Iannitti D; Chow PK; Stubbs R; Gow PJ; Masi G; Fisher KT; Lau WY; Kouladouros K; Katsanos G; Ercolani G; Rotellar F; Bilbao JI; Schoen M
Ann Surg Oncol; 2017 Sep; 24(9):2465-2473. PubMed ID: 28653161
[TBL] [Abstract][Full Text] [Related]
38. Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial.
Kondo M; Morimoto M; Kobayashi S; Ohkawa S; Hidaka H; Nakazawa T; Aikata H; Hatanaka T; Takizawa D; Matsunaga K; Okuse C; Suzuki M; Taguri M; Ishibashi T; Numata K; Maeda S; Tanaka K
BMC Cancer; 2019 Oct; 19(1):954. PubMed ID: 31615466
[TBL] [Abstract][Full Text] [Related]
39. Correlation of radiation dose and activity with clinical outcomes in metastatic colorectal cancer after selective internal radiation therapy using yttrium-90 resin microspheres.
Badiyan S; Bhooshan N; Chuong MD; Sharma N; Akhter N; Etezadi V; Hausner P; Kudryasheva S; Kaiser A; Becker S; Guerrero M; Yi BY
Nucl Med Commun; 2018 Oct; 39(10):915-920. PubMed ID: 30124600
[TBL] [Abstract][Full Text] [Related]
40. Changes in the neutrophil-to-lymphocyte ratio predict the prognosis of patients with advanced hepatocellular carcinoma treated with sorafenib.
Hong YM; Yoon KT; Hwang TH; Heo J; Woo HY; Cho M
Eur J Gastroenterol Hepatol; 2019 Oct; 31(10):1250-1255. PubMed ID: 30925530
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]